News - Boehringer Ingelheim, Licensing


Popular Filters

arGEN-X reaches two milestone payments in Shire deal and signs research agreement with Boehringer


Belgium-based biotech firm arGEN-X has reached two important success milestones in its SIMPLE Antibody…

arGEN-XBelgiumBiotechnologyBoehringer IngelheimFinancialGeneticsLicensingRare diseasesResearchShire

FORMA meets milestones under Boehringer Ingelheim cancer accord

FORMA meets milestones under Boehringer Ingelheim cancer accord


US drug discovery company FORMA Therapeutics revealed that it has achieved several discovery milestones…

Boehringer IngelheimFORMA TherapeuticsLicensingOncologyPharmaceuticalResearch

Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis


Sweden-based Athera Biotechnologies, which is 65% owned by Karolinska Development, has entered into an…

Athera BiotechnologiesBiotechnologyBoehringer IngelheimCardio-vascularKarolinska DevelopmentLicensing

Oxford BioThera and Boehringer Ingelheim collaborate; Milestone for Heptares


The UK's Oxford BioTherapeutics (OBT) and family-owned German drug major Boehringer Ingelheim have entered…

Boehringer IngelheimHeptares TherapeuticsLicensingNeurologicalOncologyOxford BioTherapeuticsPharmaceuticalResearchTakeda Pharmaceuticals

SOBI gains EMA approval for change of Kineret producer; Novartis drops NIC002 project


Swedish Orphan Biovitrum (STO: SOBI) has received approval from the European Medicines Agency for the…

BiotechnologyBoehringer IngelheimCytos BiotechnologyKineretLicensingNIC002NovartisPharmaceuticalProductionRegulationSwedish Orphan Biovitrum

Drug discovery alliances for Boehringer and Horizon Discovery; and NovAliX with Kyowa Hakko


UK-based Horizon Discovery, a provider of research tools to support the development of personalized medicines,…

Boehringer IngelheimHorizon DiscoveryKyowa Hakko KirinLicensingNovAliXOncologyPharmaceuticalResearch

Lilly and Boehringer adjust LY2605541 deal; announce positive Ph III data for empagliflozin


US drug major Eli Lilly (NYSE: LLY) and German independent drugmaker Boehringer Ingelheim said yesterday…

Boehringer IngelheimDiabetesEli LillyempagliflozinLicensingLY2605541PharmaceuticalResearch

Ensemble Thera in deal worth a potential $186 million with Boehringer Ingelheim


USA-based drug discovery firm Ensemble Therapeutics says it has initiated a research collaboration with…

Boehringer IngelheimEnsemble TherapeuticsLicensingPharmaceuticalResearch

XOMA and Servier sign manufacturing deal with Boehringer for gevokizumab


US therapeutic antibody discovery firm XOMA Corp (Nasdaq: XOMA) its partner France's Laboratoires Servier…

Boehringer IngelheimgevokizumabLicensingOphthalmicsPharmaceuticalProductionServierXOMA Corp

Boehringer Ingelheim acquires Funxional products


German family-controlled drug major Boehringer Ingelheim has entered an agreement to acquire the global…

Anti-Arthritics/RheumaticsBoehringer IngelheimFunxional TherapeuticsFX125LLicensingPharmaceuticalRespiratory and Pulmonarysomatotaxin

Ablynx extends Nanobody deal with Boehringer


Belgian drug developer Ablynx (Euronext Brussels: ABLX) yesterday announced a two-year extension of the…

AblynxBiotechnologyBoehringer IngelheimImmunologicalsLicensingOncologyPharmaceuticalRespiratory and Pulmonary

Boehringer Ingelheim links with Xencor on MAb supply


Independent German drug major Boehringer Ingelheim has entered into a collaboration agreement with USA-based,…

BiotechnologyBoehringer IngelheimLicensingPharmaceuticalXencor

Boehringer license novel HIV non-catalytic integrase inhibitors to Gilead


Two of the big names in HIV/AIDS drug research and marketing, the USA’s Gilead Sciences (Nasdaq:…

Anti-viralsBoehringer IngelheimGilead SciencesLicensingPharmaceutical

Back to top